Cholesteryl Ester Transfer Protein Inhibition for Coronary Heart Disease Prevention: Real Hope or Despair?

American Journal of Medicine

Volumn 121, Issue 8, 2008, Pages 644-646

  Frishman, William H ^a,b   Barkowski, Rakhi Shah ^a,b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DICHLORISOPRENALINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MK 0859; NICOTINIC ACID; PLACEBO; PRACTOLOL; PRONETALOL; PROPRANOLOL DERIVATIVE; TORCETRAPIB; TRIACYLGLYCEROL;

ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN SYNTHESIS INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; HUMANS; MICE; RABBITS; RISK FACTORS;

EID: 48449087714     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.02.040     Document Type: Editorial

References (23)

1. Gordon D.J., Probstfield J.L., Garrison R.G., et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
2. Badimon J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high-density lipoprotein plasma traction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
3. Barter P., Gotto A.M., LaRosa J.C., et al. for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
4. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target. A systematic review. JAMA 298 (2007) 786-798
5. Jiang X.-C., and Zhou H.-W. Plasma lipid transfer proteins. Curr Opin Lipidol 17 (2006) 302-308
6. Inazu A., Brown M., Hesler C., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323 (1990) 1234-1238
7. Tall A. Plasma cholesteryl ester transfer protein. J Lipid Res 34 (1993) 1255-1274
8. Clark R., Ruggeri R., Cunningham D., and Bamberger M. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 47 (2006) 537-552
9. Plump A., Massuci-Magoulas L., Bruce C., et al. Increased atherosclerosis in apoE and LDL receptor knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 19 (1999) 1105-1110
10. Okamoto H., Yonemori F., Wakitani K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
11. Boekholdt S., Kuivenhoven J., Wareham N., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 110 (2004) 1338-1340
12. Klerkx A., de Grooth G., Zwinderman A., et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 34 (2004) 21-28
13. Clark R., Sutfin T., Ruggeri R., et al. Raising high density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497
14. McKenney J.M., Davidson M.H., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 48 (2006) 1782-1790
15. Barter P.J., Caulfield M., Eriksson M., et al. for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
16. Nissen S., Tardiff J.C., Nicholis S., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1366
17. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
18. Bots M.L., Visseren F.L., Evans G.W., et al. for the RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomized, double-blind trial. Lancet 370 (2007) 153-160
19. Tall A.R. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 356 (2007) 1364-1366
20. Sviridov D., and Nestel P.J. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 18 (2007) 157-163
21. Ansell B.J., Fonarow G.C., and Fogelman A.M. The paradox of dysfunctional high-density lipo-protein. Curr Opin Lipidol 18 (2007) 427-434
22. Krishna R., Anderson M.S., Bergman A.J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in health individuals: two double-blind, randomized placebo-controlled phase 1 studies. Lancet 370 (2007) 1907-1914
23. Frishman W.H. A historical perspective on the development of β-adrenergic blockers. J Clin Hypertens 9 4 Suppl 3 (2007) 19-27